Tirzepatide

Tirzepatide is a synthetic peptide investigated as a dual glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist, commonly described as a dual GIP/GLP-1 receptor agonist or “twincretin.” It is a 39-amino-acid linear peptide based on the native GIP sequence, with structural modifications designed to support prolonged receptor activity and extended research half-life.

Tirzepatide has become a major compound in incretin-based metabolic research because it targets two receptor systems rather than one. GIP and GLP-1 are both incretin hormones involved in glucose-dependent insulin signaling, energy-balance pathways, adipose-tissue biology, and appetite-related regulation. By engaging both pathways, tirzepatide has been studied for its potential impact on glucose homeostasis, body-weight regulation, insulin sensitivity, and cardiometabolic markers.

Clinical and mechanistic research suggests that tirzepatide may produce strong effects on glycemic and body-weight outcomes in controlled study populations. In SURPASS-1, tirzepatide showed robust improvements in glycemic control and body weight, with a safety profile broadly consistent with GLP-1 receptor agonist research.

Specifications

Molecular Formula: C225H348N48O68
Molecular Weight: 4813 g/mol
Primary Research Targets: GIP receptor and GLP-1 receptor
Compound Class: Dual incretin receptor agonist peptide

Tirzepatide Research

Tirzepatide and Dual Incretin Signaling

Tirzepatide is designed to activate both the GIP receptor and the GLP-1 receptor. GLP-1 receptor activation is associated with glucose-dependent insulin signaling, glucagon regulation, delayed gastric emptying, and satiety-related signaling. GIP receptor activation is also involved in glucose-dependent insulin secretion and may influence adipose-tissue and energy-balance pathways. The dual-receptor model is one of the key reasons tirzepatide is viewed as distinct from single GLP-1 receptor agonists.

Tirzepatide and Glucose Regulation Research

In type 2 diabetes research settings, tirzepatide has been investigated for its effects on HbA1c, fasting glucose, insulin sensitivity, and metabolic regulation. SURPASS-1 reported significant glycemic improvements and body-weight reductions, while noting that the safety profile was generally consistent with incretin-based research.

Tirzepatide and Body-Weight Research

Tirzepatide has also been studied in body-weight management research. Reviews and trial analyses describe notable reductions in body weight across controlled study populations, likely involving central appetite pathways, delayed gastric emptying, glucose-dependent insulin signaling, and changes in energy-balance regulation. These findings have made dual GIP/GLP-1 receptor agonism a major focus of modern metabolic research.

Tirzepatide and Cardiometabolic Research

Because metabolic regulation is closely linked with blood pressure, lipid metabolism, inflammation, and cardiovascular risk markers, tirzepatide is also being studied in broader cardiometabolic frameworks. Current research is focused on understanding whether dual incretin receptor activity may influence cardiometabolic outcomes beyond glucose and body-weight changes.

References

Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes. Diabetes Ther. 2020.

Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Lancet. 2021.

Galindo RJ, et al. Insights into the mechanism of action of tirzepatide. Diabetes Therapy. 2025.

Disclaimer: This product is not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited. All information shared here is for educational and research-reference purposes only.